Lumos Pharma Inc expected to post a loss of $1.18 a share - Earnings Preview

Lumos Pharma

13/05/2024 13:54

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a
fall
in quarterly revenue when it reports  results on May 15 for the
period ending January 1 0001
    * The Austin Texas-based  company is expected to report a
56.2% decrease in revenue to $302.6 thousand from $691 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Lumos Pharma Inc is for
a loss
of $1.18 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $23.00​, above​ its last closing price of $2.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.25       -1.15      -1.17     Missed  -1.7
 Sep. 30 2023  -1.14       -1.15      -1.04     Beat    9.4
 Jun. 30 2023  -1.09       -1.10      -1.09     Beat    0.6​
 Mar. 31 2023  -1.11       -1.12      -0.89     Beat    20.8
 ​​Dec.        -0.91       -0.93      -0.99     Missed  -6.3
 31 2022                                                
 Sep. 30 2022  -1.00       -1.01      -0.86     Beat    14.7​
 Jun. 30 2022  -0.98       -0.99      -0.94     Beat    4.6
 Mar. 31 2022  -0.89       -0.89      -0.92     Missed  -3.1
 This summary was machine generated May 13 at 12:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)